Merck said to agree to $100M NuvaRing settlement

Merck (MRK +0.8%) reportedly agrees to pay $100M to settle more than 1,700 lawsuits alleging its NuvaRing contraceptive device causes potentially fatal blood clots.

The settlement, which resolves cases in federal and state courts in Missouri and New Jersey, would provide an average payout of more than $58K a case.

The settlement allows MRK to pay less than other competing contraceptive makers did to resolve lawsuits over their products; Bayer said last year it paid more than $1.6B to settle claims over its Yasmin and Yaz lines of birth control pills which allegedly caused blood clots that led to strokes and heart attacks.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs